Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Barata P, Cooney M, Tyler A, Wright J, Dreicer R, Garcia JA. Barata P, et al. Among authors: tyler a. Invest New Drugs. 2018 Jun;36(3):451-457. doi: 10.1007/s10637-018-0574-0. Epub 2018 Feb 23. Invest New Drugs. 2018. PMID: 29476383 Clinical Trial.
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.
Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P. Barata PC, et al. Among authors: tyler a. Target Oncol. 2018 Jun;13(3):353-361. doi: 10.1007/s11523-018-0561-6. Target Oncol. 2018. PMID: 29623487
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.
Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K, Tyler A, Martin A, Gilligan T, Grivas P, Ornstein M, Garcia JA, Powles T, Rini BI. Barata PC, et al. Among authors: tyler a. Br J Cancer. 2018 Jul;119(2):160-163. doi: 10.1038/s41416-018-0104-z. Epub 2018 May 24. Br J Cancer. 2018. PMID: 29795307 Free PMC article.
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.
Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi N. Alyamani M, et al. Among authors: tyler a. J Clin Invest. 2018 Aug 1;128(8):3333-3340. doi: 10.1172/JCI98319. Epub 2018 Jun 25. J Clin Invest. 2018. PMID: 29939161 Free PMC article.
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. Rini BI, et al. Among authors: tyler a. Clin Cancer Res. 2009 Oct 1;15(19):6277-83. doi: 10.1158/1078-0432.CCR-09-0717. Epub 2009 Sep 22. Clin Cancer Res. 2009. PMID: 19773375 Free PMC article. Clinical Trial.
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Ivy P, Chen HX, Dowlati A, Dreicer R. Rini BI, et al. Among authors: tyler a. J Clin Oncol. 2010 Jun 10;28(17):e284-5; author reply e286-7. doi: 10.1200/JCO.2009.27.1759. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439632 No abstract available.
447 results